The lack of efficacy of idelalisib in MM, as well as in acute myeloid leukemia and myeloproliferative neoplasms, is attributed to a highly variable p110-δ active site and a high degree of conformational flexibility that leads to poor inhibitor binding. Here, PIK3CD is linked to Miyoshi myopathy.